Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma

Results from a Phase 1b/2 Study of Ibrutinib Combination Therapy in Advanced Urothelial Carcinoma

Ibrutinib is a first-in-class Bruton’s tyrosine kinase inhibitor approved for the treatment of various B-cell malignancies and chronic graft-versus-host disease. We evaluated the safety and efficacy of ibrutinib, alone or combined with standard-of-care regimens, in adults with advanced urothelial ca...

Full description

Bibliographic Details
Main Authors: Nataliya Mar, Yousef Zakharia, Alejandro Falcon, Rafael Morales-Barrera, Begona Mellado, Ignacio Duran, Do-Youn Oh, Stephen K. Williamson, Pablo Gajate, Hendrik-Tobias Arkenau, Robert J. Jones, Min Yuen Teo, Tolga Turan, Robert T. McLaughlin, Hillary M. Peltier, Elizabeth Chong, Harisha Atluri, James P. Dean, Daniel Castellano
Format: Article
Language:English
Published: MDPI AG 2023-05-01
Series:Cancers
Subjects:
urothelial carcinoma
ibrutinib
paclitaxel
pembrolizumab
Online Access:https://www.mdpi.com/2072-6694/15/11/2978

Internet

https://www.mdpi.com/2072-6694/15/11/2978

Similar Items